nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—CYP3A4—type 2 diabetes mellitus	0.297	1	CbGaD
Pimecrolimus—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0475	0.152	CbGbCtD
Pimecrolimus—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0424	0.136	CbGbCtD
Pimecrolimus—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0388	0.124	CbGbCtD
Pimecrolimus—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.0339	0.109	CbGbCtD
Pimecrolimus—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0306	0.0982	CbGbCtD
Pimecrolimus—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0232	0.0744	CbGbCtD
Pimecrolimus—CYP3A4—Orlistat—type 2 diabetes mellitus	0.0223	0.0713	CbGbCtD
Pimecrolimus—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0223	0.0713	CbGbCtD
Pimecrolimus—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.0211	0.0675	CbGbCtD
Pimecrolimus—CYP3A4—Glyburide—type 2 diabetes mellitus	0.0157	0.0503	CbGbCtD
Pimecrolimus—CYP3A4—Losartan—type 2 diabetes mellitus	0.0143	0.046	CbGbCtD
Pimecrolimus—MTOR—leg—type 2 diabetes mellitus	0.0108	0.239	CbGeAlD
Pimecrolimus—MTOR—hindlimb—type 2 diabetes mellitus	0.00962	0.214	CbGeAlD
Pimecrolimus—MTOR—retina—type 2 diabetes mellitus	0.00242	0.0538	CbGeAlD
Pimecrolimus—FKBP1A—retina—type 2 diabetes mellitus	0.00218	0.0484	CbGeAlD
Pimecrolimus—MTOR—cardiovascular system—type 2 diabetes mellitus	0.00205	0.0455	CbGeAlD
Pimecrolimus—MTOR—kidney—type 2 diabetes mellitus	0.00201	0.0445	CbGeAlD
Pimecrolimus—MTOR—pancreas—type 2 diabetes mellitus	0.00199	0.0442	CbGeAlD
Pimecrolimus—FKBP1A—cardiovascular system—type 2 diabetes mellitus	0.00184	0.0409	CbGeAlD
Pimecrolimus—MTOR—adipose tissue—type 2 diabetes mellitus	0.00181	0.0401	CbGeAlD
Pimecrolimus—FKBP1A—kidney—type 2 diabetes mellitus	0.0018	0.04	CbGeAlD
Pimecrolimus—FKBP1A—pancreas—type 2 diabetes mellitus	0.00179	0.0398	CbGeAlD
Pimecrolimus—FKBP1A—cortex of kidney—type 2 diabetes mellitus	0.00176	0.039	CbGeAlD
Pimecrolimus—FKBP1A—adipose tissue—type 2 diabetes mellitus	0.00163	0.0361	CbGeAlD
Pimecrolimus—MTOR—liver—type 2 diabetes mellitus	0.00127	0.0281	CbGeAlD
Pimecrolimus—FKBP1A—liver—type 2 diabetes mellitus	0.00114	0.0253	CbGeAlD
Pimecrolimus—Everolimus—CYP3A4—type 2 diabetes mellitus	0.000757	0.296	CrCbGaD
Pimecrolimus—CYP3A4—kidney—type 2 diabetes mellitus	0.00059	0.0131	CbGeAlD
Pimecrolimus—Temsirolimus—CYP3A4—type 2 diabetes mellitus	0.000511	0.2	CrCbGaD
Pimecrolimus—Sirolimus—CYP3A4—type 2 diabetes mellitus	0.00045	0.176	CrCbGaD
Pimecrolimus—Tacrolimus—CYP3A4—type 2 diabetes mellitus	0.00045	0.176	CrCbGaD
Pimecrolimus—Tacrolimus—ALB—type 2 diabetes mellitus	0.000393	0.153	CrCbGaD
Pimecrolimus—CYP3A4—liver—type 2 diabetes mellitus	0.000373	0.00827	CbGeAlD
Pimecrolimus—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	0.00021	0.00104	CcSEcCtD
Pimecrolimus—Immune system disorder—Metformin—type 2 diabetes mellitus	0.00021	0.00104	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Metformin—type 2 diabetes mellitus	0.00021	0.00104	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.000208	0.00103	CcSEcCtD
Pimecrolimus—Rhinitis—Losartan—type 2 diabetes mellitus	0.000207	0.00102	CcSEcCtD
Pimecrolimus—Arthralgia—Gliclazide—type 2 diabetes mellitus	0.000206	0.00102	CcSEcCtD
Pimecrolimus—Rash—Rosiglitazone—type 2 diabetes mellitus	0.000206	0.00102	CcSEcCtD
Pimecrolimus—Constipation—Bromocriptine—type 2 diabetes mellitus	0.000206	0.00102	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Ramipril—type 2 diabetes mellitus	0.000206	0.00102	CcSEcCtD
Pimecrolimus—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.000206	0.00102	CcSEcCtD
Pimecrolimus—Nausea—Repaglinide—type 2 diabetes mellitus	0.000205	0.00101	CcSEcCtD
Pimecrolimus—Pharyngitis—Losartan—type 2 diabetes mellitus	0.000205	0.00101	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	0.000205	0.00101	CcSEcCtD
Pimecrolimus—Headache—Rosiglitazone—type 2 diabetes mellitus	0.000205	0.00101	CcSEcCtD
Pimecrolimus—Flushing—Irbesartan—type 2 diabetes mellitus	0.000204	0.00101	CcSEcCtD
Pimecrolimus—Angioedema—Valsartan—type 2 diabetes mellitus	0.000203	0.001	CcSEcCtD
Pimecrolimus—Malnutrition—Metformin—type 2 diabetes mellitus	0.000202	0.001	CcSEcCtD
Pimecrolimus—Erythema—Metformin—type 2 diabetes mellitus	0.000202	0.001	CcSEcCtD
Pimecrolimus—Pruritus—Glipizide—type 2 diabetes mellitus	0.000202	0.000999	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Ramipril—type 2 diabetes mellitus	0.000202	0.000998	CcSEcCtD
Pimecrolimus—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.000202	0.000997	CcSEcCtD
Pimecrolimus—Angioedema—Orlistat—type 2 diabetes mellitus	0.000201	0.000992	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Glyburide—type 2 diabetes mellitus	0.0002	0.00099	CcSEcCtD
Pimecrolimus—Immune system disorder—Irbesartan—type 2 diabetes mellitus	0.000198	0.000979	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Irbesartan—type 2 diabetes mellitus	0.000198	0.000977	CcSEcCtD
Pimecrolimus—Paraesthesia—Glyburide—type 2 diabetes mellitus	0.000198	0.000976	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	0.000197	0.000972	CcSEcCtD
Pimecrolimus—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.000197	0.000971	CcSEcCtD
Pimecrolimus—Infection—Gliclazide—type 2 diabetes mellitus	0.000196	0.000969	CcSEcCtD
Pimecrolimus—Dyspnoea—Glyburide—type 2 diabetes mellitus	0.000196	0.000969	CcSEcCtD
Pimecrolimus—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.000196	0.000968	CcSEcCtD
Pimecrolimus—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000196	0.000966	CcSEcCtD
Pimecrolimus—Cough—Valsartan—type 2 diabetes mellitus	0.000194	0.000959	CcSEcCtD
Pimecrolimus—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000194	0.000958	CcSEcCtD
Pimecrolimus—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.000194	0.000957	CcSEcCtD
Pimecrolimus—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.000192	0.000948	CcSEcCtD
Pimecrolimus—Conjunctivitis—Ramipril—type 2 diabetes mellitus	0.000192	0.000948	CcSEcCtD
Pimecrolimus—Cough—Orlistat—type 2 diabetes mellitus	0.000192	0.000947	CcSEcCtD
Pimecrolimus—Flushing—Losartan—type 2 diabetes mellitus	0.000192	0.000947	CcSEcCtD
Pimecrolimus—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.000191	0.000944	CcSEcCtD
Pimecrolimus—Malnutrition—Irbesartan—type 2 diabetes mellitus	0.000191	0.000944	CcSEcCtD
Pimecrolimus—Erythema—Irbesartan—type 2 diabetes mellitus	0.000191	0.000944	CcSEcCtD
Pimecrolimus—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	0.00019	0.00094	CcSEcCtD
Pimecrolimus—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	0.00019	0.00094	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.00019	0.000938	CcSEcCtD
Pimecrolimus—Arthralgia—Valsartan—type 2 diabetes mellitus	0.000189	0.000935	CcSEcCtD
Pimecrolimus—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000189	0.000932	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000188	0.000929	CcSEcCtD
Pimecrolimus—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000187	0.000926	CcSEcCtD
Pimecrolimus—Epistaxis—Ramipril—type 2 diabetes mellitus	0.000186	0.000919	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000186	0.000918	CcSEcCtD
Pimecrolimus—Sinusitis—Ramipril—type 2 diabetes mellitus	0.000185	0.000915	CcSEcCtD
Pimecrolimus—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000182	0.000902	CcSEcCtD
Pimecrolimus—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000182	0.000899	CcSEcCtD
Pimecrolimus—Vomiting—Glipizide—type 2 diabetes mellitus	0.000182	0.000898	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	0.000181	0.000896	CcSEcCtD
Pimecrolimus—Oedema—Valsartan—type 2 diabetes mellitus	0.000181	0.000896	CcSEcCtD
Pimecrolimus—Infection—Valsartan—type 2 diabetes mellitus	0.00018	0.000891	CcSEcCtD
Pimecrolimus—Rash—Glipizide—type 2 diabetes mellitus	0.00018	0.00089	CcSEcCtD
Pimecrolimus—Dermatitis—Glipizide—type 2 diabetes mellitus	0.00018	0.000889	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	0.00018	0.000889	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.00018	0.000889	CcSEcCtD
Pimecrolimus—Erythema—Losartan—type 2 diabetes mellitus	0.00018	0.000888	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.000179	0.000886	CcSEcCtD
Pimecrolimus—Oedema—Orlistat—type 2 diabetes mellitus	0.000179	0.000886	CcSEcCtD
Pimecrolimus—Headache—Glipizide—type 2 diabetes mellitus	0.000179	0.000885	CcSEcCtD
Pimecrolimus—Infection—Orlistat—type 2 diabetes mellitus	0.000178	0.00088	CcSEcCtD
Pimecrolimus—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000178	0.000879	CcSEcCtD
Pimecrolimus—Paraesthesia—Gliclazide—type 2 diabetes mellitus	0.000177	0.000876	CcSEcCtD
Pimecrolimus—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000176	0.000871	CcSEcCtD
Pimecrolimus—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000176	0.00087	CcSEcCtD
Pimecrolimus—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000176	0.000869	CcSEcCtD
Pimecrolimus—Urticaria—Glyburide—type 2 diabetes mellitus	0.000175	0.000863	CcSEcCtD
Pimecrolimus—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000175	0.000863	CcSEcCtD
Pimecrolimus—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000174	0.00086	CcSEcCtD
Pimecrolimus—Back pain—Losartan—type 2 diabetes mellitus	0.000174	0.000859	CcSEcCtD
Pimecrolimus—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000174	0.000859	CcSEcCtD
Pimecrolimus—Headache—Pioglitazone—type 2 diabetes mellitus	0.000172	0.000847	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000171	0.000846	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000171	0.000842	CcSEcCtD
Pimecrolimus—Nausea—Glipizide—type 2 diabetes mellitus	0.00017	0.000839	CcSEcCtD
Pimecrolimus—Vomiting—Glimepiride—type 2 diabetes mellitus	0.00017	0.000838	CcSEcCtD
Pimecrolimus—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000169	0.000835	CcSEcCtD
Pimecrolimus—Constipation—Gliclazide—type 2 diabetes mellitus	0.000169	0.000834	CcSEcCtD
Pimecrolimus—Pain—Gliclazide—type 2 diabetes mellitus	0.000169	0.000834	CcSEcCtD
Pimecrolimus—Rash—Glimepiride—type 2 diabetes mellitus	0.000168	0.000831	CcSEcCtD
Pimecrolimus—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000168	0.00083	CcSEcCtD
Pimecrolimus—Rash—Sitagliptin—type 2 diabetes mellitus	0.000168	0.000828	CcSEcCtD
Pimecrolimus—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000167	0.000827	CcSEcCtD
Pimecrolimus—Headache—Glimepiride—type 2 diabetes mellitus	0.000167	0.000825	CcSEcCtD
Pimecrolimus—Cough—Irbesartan—type 2 diabetes mellitus	0.000167	0.000824	CcSEcCtD
Pimecrolimus—Headache—Sitagliptin—type 2 diabetes mellitus	0.000167	0.000823	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000165	0.000817	CcSEcCtD
Pimecrolimus—Oedema—Metformin—type 2 diabetes mellitus	0.000165	0.000816	CcSEcCtD
Pimecrolimus—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000165	0.000813	CcSEcCtD
Pimecrolimus—Flushing—Ramipril—type 2 diabetes mellitus	0.000164	0.000812	CcSEcCtD
Pimecrolimus—Angioedema—Losartan—type 2 diabetes mellitus	0.000164	0.000812	CcSEcCtD
Pimecrolimus—Infection—Metformin—type 2 diabetes mellitus	0.000164	0.000811	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000163	0.000807	CcSEcCtD
Pimecrolimus—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000163	0.000805	CcSEcCtD
Pimecrolimus—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000163	0.000804	CcSEcCtD
Pimecrolimus—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000162	0.000801	CcSEcCtD
Pimecrolimus—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000162	0.000801	CcSEcCtD
Pimecrolimus—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000162	0.000799	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000162	0.000798	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000162	0.000798	CcSEcCtD
Pimecrolimus—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000161	0.000795	CcSEcCtD
Pimecrolimus—Skin disorder—Metformin—type 2 diabetes mellitus	0.000161	0.000793	CcSEcCtD
Pimecrolimus—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.00016	0.00079	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.00016	0.000789	CcSEcCtD
Pimecrolimus—Nausea—Glimepiride—type 2 diabetes mellitus	0.000158	0.000783	CcSEcCtD
Pimecrolimus—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000158	0.00078	CcSEcCtD
Pimecrolimus—Cough—Losartan—type 2 diabetes mellitus	0.000157	0.000775	CcSEcCtD
Pimecrolimus—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000157	0.000775	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000157	0.000774	CcSEcCtD
Pimecrolimus—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000156	0.000771	CcSEcCtD
Pimecrolimus—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000156	0.000771	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000156	0.00077	CcSEcCtD
Pimecrolimus—Oedema—Irbesartan—type 2 diabetes mellitus	0.000156	0.00077	CcSEcCtD
Pimecrolimus—Pruritus—Glyburide—type 2 diabetes mellitus	0.000156	0.000769	CcSEcCtD
Pimecrolimus—Constipation—Valsartan—type 2 diabetes mellitus	0.000155	0.000767	CcSEcCtD
Pimecrolimus—Infection—Irbesartan—type 2 diabetes mellitus	0.000155	0.000765	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000155	0.000765	CcSEcCtD
Pimecrolimus—Erythema—Ramipril—type 2 diabetes mellitus	0.000154	0.000762	CcSEcCtD
Pimecrolimus—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000154	0.000762	CcSEcCtD
Pimecrolimus—Pain—Orlistat—type 2 diabetes mellitus	0.000153	0.000758	CcSEcCtD
Pimecrolimus—Arthralgia—Losartan—type 2 diabetes mellitus	0.000153	0.000756	CcSEcCtD
Pimecrolimus—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000153	0.000756	CcSEcCtD
Pimecrolimus—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000153	0.000756	CcSEcCtD
Pimecrolimus—Rash—Bromocriptine—type 2 diabetes mellitus	0.000152	0.000749	CcSEcCtD
Pimecrolimus—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000152	0.000749	CcSEcCtD
Pimecrolimus—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000151	0.000748	CcSEcCtD
Pimecrolimus—Headache—Bromocriptine—type 2 diabetes mellitus	0.000151	0.000745	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000151	0.000744	CcSEcCtD
Pimecrolimus—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.00015	0.000744	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000148	0.000733	CcSEcCtD
Pimecrolimus—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000148	0.000733	CcSEcCtD
Pimecrolimus—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000147	0.000728	CcSEcCtD
Pimecrolimus—Oedema—Losartan—type 2 diabetes mellitus	0.000147	0.000725	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000147	0.000725	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000147	0.000724	CcSEcCtD
Pimecrolimus—Infection—Losartan—type 2 diabetes mellitus	0.000146	0.00072	CcSEcCtD
Pimecrolimus—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000146	0.000719	CcSEcCtD
Pimecrolimus—Urticaria—Valsartan—type 2 diabetes mellitus	0.000144	0.000712	CcSEcCtD
Pimecrolimus—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000144	0.000711	CcSEcCtD
Pimecrolimus—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000143	0.000709	CcSEcCtD
Pimecrolimus—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000143	0.000706	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000143	0.000705	CcSEcCtD
Pimecrolimus—Urticaria—Orlistat—type 2 diabetes mellitus	0.000142	0.000704	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000142	0.000702	CcSEcCtD
Pimecrolimus—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.000142	0.0007	CcSEcCtD
Pimecrolimus—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000142	0.0007	CcSEcCtD
Pimecrolimus—Constipation—Metformin—type 2 diabetes mellitus	0.000141	0.000698	CcSEcCtD
Pimecrolimus—Angioedema—Ramipril—type 2 diabetes mellitus	0.000141	0.000696	CcSEcCtD
Pimecrolimus—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.00014	0.000692	CcSEcCtD
Pimecrolimus—Vomiting—Glyburide—type 2 diabetes mellitus	0.00014	0.000691	CcSEcCtD
Pimecrolimus—Pruritus—Gliclazide—type 2 diabetes mellitus	0.00014	0.00069	CcSEcCtD
Pimecrolimus—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000139	0.000687	CcSEcCtD
Pimecrolimus—Rash—Glyburide—type 2 diabetes mellitus	0.000139	0.000685	CcSEcCtD
Pimecrolimus—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000139	0.000685	CcSEcCtD
Pimecrolimus—Headache—Glyburide—type 2 diabetes mellitus	0.000138	0.000681	CcSEcCtD
Pimecrolimus—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000135	0.000668	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000135	0.000668	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000135	0.000665	CcSEcCtD
Pimecrolimus—Cough—Ramipril—type 2 diabetes mellitus	0.000135	0.000665	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000134	0.000661	CcSEcCtD
Pimecrolimus—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000134	0.00066	CcSEcCtD
Pimecrolimus—Pain—Irbesartan—type 2 diabetes mellitus	0.000133	0.000659	CcSEcCtD
Pimecrolimus—Constipation—Irbesartan—type 2 diabetes mellitus	0.000133	0.000659	CcSEcCtD
Pimecrolimus—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000132	0.000653	CcSEcCtD
Pimecrolimus—Paraesthesia—Losartan—type 2 diabetes mellitus	0.000132	0.000651	CcSEcCtD
Pimecrolimus—Urticaria—Metformin—type 2 diabetes mellitus	0.000131	0.000649	CcSEcCtD
Pimecrolimus—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000131	0.000649	CcSEcCtD
Pimecrolimus—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000131	0.000646	CcSEcCtD
Pimecrolimus—Nausea—Glyburide—type 2 diabetes mellitus	0.000131	0.000645	CcSEcCtD
Pimecrolimus—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000131	0.000645	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.00013	0.000644	CcSEcCtD
Pimecrolimus—Pruritus—Valsartan—type 2 diabetes mellitus	0.000128	0.000634	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.000128	0.00063	CcSEcCtD
Pimecrolimus—Pruritus—Orlistat—type 2 diabetes mellitus	0.000127	0.000627	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.000126	0.000622	CcSEcCtD
Pimecrolimus—Oedema—Ramipril—type 2 diabetes mellitus	0.000126	0.000622	CcSEcCtD
Pimecrolimus—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000126	0.00062	CcSEcCtD
Pimecrolimus—Constipation—Losartan—type 2 diabetes mellitus	0.000126	0.00062	CcSEcCtD
Pimecrolimus—Pain—Losartan—type 2 diabetes mellitus	0.000126	0.00062	CcSEcCtD
Pimecrolimus—Rash—Gliclazide—type 2 diabetes mellitus	0.000125	0.000615	CcSEcCtD
Pimecrolimus—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000124	0.000615	CcSEcCtD
Pimecrolimus—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000124	0.000613	CcSEcCtD
Pimecrolimus—Urticaria—Irbesartan—type 2 diabetes mellitus	0.000124	0.000612	CcSEcCtD
Pimecrolimus—Headache—Gliclazide—type 2 diabetes mellitus	0.000124	0.000611	CcSEcCtD
Pimecrolimus—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000123	0.00061	CcSEcCtD
Pimecrolimus—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000123	0.000609	CcSEcCtD
Pimecrolimus—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000123	0.000609	CcSEcCtD
Pimecrolimus—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000123	0.000606	CcSEcCtD
Pimecrolimus—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000122	0.000604	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.00012	0.000593	CcSEcCtD
Pimecrolimus—Nausea—Gliclazide—type 2 diabetes mellitus	0.000117	0.00058	CcSEcCtD
Pimecrolimus—Pruritus—Metformin—type 2 diabetes mellitus	0.000117	0.000578	CcSEcCtD
Pimecrolimus—Urticaria—Losartan—type 2 diabetes mellitus	0.000117	0.000576	CcSEcCtD
Pimecrolimus—Abdominal pain—Losartan—type 2 diabetes mellitus	0.000116	0.000573	CcSEcCtD
Pimecrolimus—Body temperature increased—Losartan—type 2 diabetes mellitus	0.000116	0.000573	CcSEcCtD
Pimecrolimus—Vomiting—Valsartan—type 2 diabetes mellitus	0.000115	0.00057	CcSEcCtD
Pimecrolimus—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000115	0.000568	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.000115	0.000566	CcSEcCtD
Pimecrolimus—Rash—Valsartan—type 2 diabetes mellitus	0.000114	0.000565	CcSEcCtD
Pimecrolimus—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000114	0.000565	CcSEcCtD
Pimecrolimus—Vomiting—Orlistat—type 2 diabetes mellitus	0.000114	0.000563	CcSEcCtD
Pimecrolimus—Headache—Valsartan—type 2 diabetes mellitus	0.000114	0.000562	CcSEcCtD
Pimecrolimus—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000113	0.000559	CcSEcCtD
Pimecrolimus—Rash—Orlistat—type 2 diabetes mellitus	0.000113	0.000559	CcSEcCtD
Pimecrolimus—Paraesthesia—Ramipril—type 2 diabetes mellitus	0.000113	0.000558	CcSEcCtD
Pimecrolimus—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000113	0.000558	CcSEcCtD
Pimecrolimus—Headache—Orlistat—type 2 diabetes mellitus	0.000112	0.000555	CcSEcCtD
Pimecrolimus—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000112	0.000554	CcSEcCtD
Pimecrolimus—Pruritus—Irbesartan—type 2 diabetes mellitus	0.00011	0.000545	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000109	0.000537	CcSEcCtD
Pimecrolimus—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000108	0.000534	CcSEcCtD
Pimecrolimus—Nausea—Valsartan—type 2 diabetes mellitus	0.000108	0.000533	CcSEcCtD
Pimecrolimus—Constipation—Ramipril—type 2 diabetes mellitus	0.000108	0.000532	CcSEcCtD
Pimecrolimus—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000107	0.000527	CcSEcCtD
Pimecrolimus—Nausea—Orlistat—type 2 diabetes mellitus	0.000107	0.000526	CcSEcCtD
Pimecrolimus—Vomiting—Metformin—type 2 diabetes mellitus	0.000105	0.000519	CcSEcCtD
Pimecrolimus—Rash—Metformin—type 2 diabetes mellitus	0.000104	0.000515	CcSEcCtD
Pimecrolimus—Dermatitis—Metformin—type 2 diabetes mellitus	0.000104	0.000514	CcSEcCtD
Pimecrolimus—Pruritus—Losartan—type 2 diabetes mellitus	0.000104	0.000513	CcSEcCtD
Pimecrolimus—Headache—Metformin—type 2 diabetes mellitus	0.000104	0.000511	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	0.000103	0.000508	CcSEcCtD
Pimecrolimus—Diarrhoea—Losartan—type 2 diabetes mellitus	0.0001	0.000496	CcSEcCtD
Pimecrolimus—Urticaria—Ramipril—type 2 diabetes mellitus	0.0001	0.000494	CcSEcCtD
Pimecrolimus—Body temperature increased—Ramipril—type 2 diabetes mellitus	9.95e-05	0.000491	CcSEcCtD
Pimecrolimus—Abdominal pain—Ramipril—type 2 diabetes mellitus	9.95e-05	0.000491	CcSEcCtD
Pimecrolimus—Vomiting—Irbesartan—type 2 diabetes mellitus	9.92e-05	0.00049	CcSEcCtD
Pimecrolimus—Rash—Irbesartan—type 2 diabetes mellitus	9.83e-05	0.000486	CcSEcCtD
Pimecrolimus—Dermatitis—Irbesartan—type 2 diabetes mellitus	9.82e-05	0.000485	CcSEcCtD
Pimecrolimus—Nausea—Metformin—type 2 diabetes mellitus	9.82e-05	0.000485	CcSEcCtD
Pimecrolimus—Headache—Irbesartan—type 2 diabetes mellitus	9.77e-05	0.000483	CcSEcCtD
Pimecrolimus—Vomiting—Losartan—type 2 diabetes mellitus	9.33e-05	0.000461	CcSEcCtD
Pimecrolimus—Hypersensitivity—Ramipril—type 2 diabetes mellitus	9.27e-05	0.000458	CcSEcCtD
Pimecrolimus—Nausea—Irbesartan—type 2 diabetes mellitus	9.26e-05	0.000458	CcSEcCtD
Pimecrolimus—Rash—Losartan—type 2 diabetes mellitus	9.25e-05	0.000457	CcSEcCtD
Pimecrolimus—Dermatitis—Losartan—type 2 diabetes mellitus	9.24e-05	0.000457	CcSEcCtD
Pimecrolimus—Headache—Losartan—type 2 diabetes mellitus	9.19e-05	0.000454	CcSEcCtD
Pimecrolimus—Pruritus—Ramipril—type 2 diabetes mellitus	8.9e-05	0.00044	CcSEcCtD
Pimecrolimus—Nausea—Losartan—type 2 diabetes mellitus	8.72e-05	0.000431	CcSEcCtD
Pimecrolimus—Diarrhoea—Ramipril—type 2 diabetes mellitus	8.61e-05	0.000425	CcSEcCtD
Pimecrolimus—Vomiting—Ramipril—type 2 diabetes mellitus	8e-05	0.000395	CcSEcCtD
Pimecrolimus—Rash—Ramipril—type 2 diabetes mellitus	7.93e-05	0.000392	CcSEcCtD
Pimecrolimus—Dermatitis—Ramipril—type 2 diabetes mellitus	7.93e-05	0.000392	CcSEcCtD
Pimecrolimus—Headache—Ramipril—type 2 diabetes mellitus	7.88e-05	0.000389	CcSEcCtD
Pimecrolimus—Nausea—Ramipril—type 2 diabetes mellitus	7.47e-05	0.000369	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—INS—type 2 diabetes mellitus	2.46e-05	0.000175	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCKAR—type 2 diabetes mellitus	2.45e-05	0.000174	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—LPL—type 2 diabetes mellitus	2.41e-05	0.000171	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT2—type 2 diabetes mellitus	2.39e-05	0.00017	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT2—type 2 diabetes mellitus	2.38e-05	0.000169	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—type 2 diabetes mellitus	2.37e-05	0.000168	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	2.36e-05	0.000167	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SERPINE1—type 2 diabetes mellitus	2.26e-05	0.000161	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	2.26e-05	0.00016	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3R1—type 2 diabetes mellitus	2.26e-05	0.00016	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	2.22e-05	0.000158	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCR5—type 2 diabetes mellitus	2.22e-05	0.000158	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IAPP—type 2 diabetes mellitus	2.21e-05	0.000157	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—INSR—type 2 diabetes mellitus	2.19e-05	0.000156	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—BCL2—type 2 diabetes mellitus	2.18e-05	0.000154	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3R1—type 2 diabetes mellitus	2.17e-05	0.000154	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—C3—type 2 diabetes mellitus	2.17e-05	0.000154	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3R1—type 2 diabetes mellitus	2.16e-05	0.000153	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NOS3—type 2 diabetes mellitus	2.16e-05	0.000153	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TRPC6—type 2 diabetes mellitus	2.15e-05	0.000153	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TGFBR2—type 2 diabetes mellitus	2.15e-05	0.000152	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AGTR2—type 2 diabetes mellitus	2.14e-05	0.000152	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—RELA—type 2 diabetes mellitus	2.13e-05	0.000151	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—IL6—type 2 diabetes mellitus	2.1e-05	0.000149	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN2B—type 2 diabetes mellitus	2.08e-05	0.000148	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.07e-05	0.000147	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.06e-05	0.000146	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AGT—type 2 diabetes mellitus	2.06e-05	0.000146	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AGER—type 2 diabetes mellitus	2.06e-05	0.000146	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ADCY5—type 2 diabetes mellitus	2.05e-05	0.000146	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EDNRB—type 2 diabetes mellitus	2.05e-05	0.000146	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—RELA—type 2 diabetes mellitus	2.04e-05	0.000145	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.03e-05	0.000144	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APOB—type 2 diabetes mellitus	2.03e-05	0.000144	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—APOE—type 2 diabetes mellitus	2.02e-05	0.000143	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—LEP—type 2 diabetes mellitus	2.02e-05	0.000143	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	2e-05	0.000142	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PSMD6—type 2 diabetes mellitus	1.99e-05	0.000141	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HTR2C—type 2 diabetes mellitus	1.99e-05	0.000141	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD36—type 2 diabetes mellitus	1.99e-05	0.000141	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTGS2—type 2 diabetes mellitus	1.98e-05	0.00014	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IL6—type 2 diabetes mellitus	1.97e-05	0.00014	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PPP2CA—type 2 diabetes mellitus	1.97e-05	0.00014	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—BHMT—type 2 diabetes mellitus	1.95e-05	0.000139	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.94e-05	0.000138	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—LPL—type 2 diabetes mellitus	1.93e-05	0.000137	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.93e-05	0.000137	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.9e-05	0.000135	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	1.9e-05	0.000135	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ADCY5—type 2 diabetes mellitus	1.89e-05	0.000134	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.89e-05	0.000134	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.89e-05	0.000134	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—C3—type 2 diabetes mellitus	1.89e-05	0.000134	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.86e-05	0.000132	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—AKT1—type 2 diabetes mellitus	1.82e-05	0.000129	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PPP2CA—type 2 diabetes mellitus	1.82e-05	0.000129	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BCL2L1—type 2 diabetes mellitus	1.81e-05	0.000128	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.8e-05	0.000128	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CRP—type 2 diabetes mellitus	1.8e-05	0.000127	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IRS2—type 2 diabetes mellitus	1.8e-05	0.000127	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NFKB1—type 2 diabetes mellitus	1.79e-05	0.000127	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CCR5—type 2 diabetes mellitus	1.78e-05	0.000127	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CALM1—type 2 diabetes mellitus	1.76e-05	0.000125	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.76e-05	0.000125	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MTHFR—type 2 diabetes mellitus	1.74e-05	0.000124	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GCG—type 2 diabetes mellitus	1.73e-05	0.000123	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.73e-05	0.000123	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—INS—type 2 diabetes mellitus	1.73e-05	0.000122	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—NFKB1—type 2 diabetes mellitus	1.72e-05	0.000122	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AANAT—type 2 diabetes mellitus	1.71e-05	0.000121	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGDS—type 2 diabetes mellitus	1.71e-05	0.000121	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.7e-05	0.000121	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.7e-05	0.00012	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.69e-05	0.00012	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—SRC—type 2 diabetes mellitus	1.67e-05	0.000119	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.67e-05	0.000118	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.67e-05	0.000118	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HIF1A—type 2 diabetes mellitus	1.66e-05	0.000118	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IRS2—type 2 diabetes mellitus	1.66e-05	0.000118	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PRKCB—type 2 diabetes mellitus	1.66e-05	0.000118	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ICAM1—type 2 diabetes mellitus	1.65e-05	0.000117	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CALM1—type 2 diabetes mellitus	1.63e-05	0.000116	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APOE—type 2 diabetes mellitus	1.62e-05	0.000115	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPD2—type 2 diabetes mellitus	1.62e-05	0.000115	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CDO1—type 2 diabetes mellitus	1.62e-05	0.000115	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—SRC—type 2 diabetes mellitus	1.61e-05	0.000114	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APOA1—type 2 diabetes mellitus	1.6e-05	0.000114	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SRC—type 2 diabetes mellitus	1.6e-05	0.000113	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.58e-05	0.000112	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IRS1—type 2 diabetes mellitus	1.57e-05	0.000111	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AK1—type 2 diabetes mellitus	1.54e-05	0.00011	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.51e-05	0.000107	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.51e-05	0.000107	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS2—type 2 diabetes mellitus	1.51e-05	0.000107	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.5e-05	0.000107	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.49e-05	0.000106	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CASP8—type 2 diabetes mellitus	1.48e-05	0.000105	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AVP—type 2 diabetes mellitus	1.47e-05	0.000104	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.47e-05	0.000104	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EGFR—type 2 diabetes mellitus	1.46e-05	0.000104	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.46e-05	0.000104	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.46e-05	0.000103	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT2—type 2 diabetes mellitus	1.45e-05	0.000103	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IRS1—type 2 diabetes mellitus	1.45e-05	0.000103	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TGFB1—type 2 diabetes mellitus	1.43e-05	0.000101	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC5A4—type 2 diabetes mellitus	1.42e-05	0.000101	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MAT1A—type 2 diabetes mellitus	1.42e-05	0.000101	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.42e-05	0.000101	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOB—type 2 diabetes mellitus	1.42e-05	0.000101	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.41e-05	0.0001	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—EGFR—type 2 diabetes mellitus	1.41e-05	9.99e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EGFR—type 2 diabetes mellitus	1.4e-05	9.94e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.4e-05	9.91e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—INS—type 2 diabetes mellitus	1.39e-05	9.84e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ND1—type 2 diabetes mellitus	1.38e-05	9.77e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—G6PC—type 2 diabetes mellitus	1.38e-05	9.77e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPP1R3C—type 2 diabetes mellitus	1.38e-05	9.77e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HBA2—type 2 diabetes mellitus	1.38e-05	9.77e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ENPP1—type 2 diabetes mellitus	1.38e-05	9.77e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LPL—type 2 diabetes mellitus	1.35e-05	9.62e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT2—type 2 diabetes mellitus	1.34e-05	9.51e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GCGR—type 2 diabetes mellitus	1.33e-05	9.46e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.33e-05	9.42e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3R1—type 2 diabetes mellitus	1.32e-05	9.34e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.28e-05	9.12e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SERPINE1—type 2 diabetes mellitus	1.27e-05	9.03e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.27e-05	9.02e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BCL2—type 2 diabetes mellitus	1.27e-05	8.99e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	1.26e-05	8.93e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	1.26e-05	8.93e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.25e-05	8.86e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RELA—type 2 diabetes mellitus	1.24e-05	8.79e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	1.23e-05	8.71e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—C3—type 2 diabetes mellitus	1.22e-05	8.66e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS3—type 2 diabetes mellitus	1.22e-05	8.63e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3R1—type 2 diabetes mellitus	1.22e-05	8.63e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.21e-05	8.62e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.2e-05	8.53e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	1.17e-05	8.3e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	1.17e-05	8.3e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	1.17e-05	8.3e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.16e-05	8.26e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.16e-05	8.24e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AGT—type 2 diabetes mellitus	1.16e-05	8.23e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.14e-05	8.09e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOE—type 2 diabetes mellitus	1.14e-05	8.06e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LEP—type 2 diabetes mellitus	1.14e-05	8.06e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—type 2 diabetes mellitus	1.13e-05	7.99e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.12e-05	7.97e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	1.12e-05	7.96e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	1.12e-05	7.96e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.12e-05	7.94e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—type 2 diabetes mellitus	1.11e-05	7.89e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.09e-05	7.74e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	1.08e-05	7.66e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	1.08e-05	7.66e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—type 2 diabetes mellitus	1.08e-05	7.64e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.07e-05	7.6e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	1.06e-05	7.53e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NFKB1—type 2 diabetes mellitus	1.04e-05	7.42e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	1.04e-05	7.4e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	1.04e-05	7.4e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	1.04e-05	7.4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT1—type 2 diabetes mellitus	1.04e-05	7.37e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.01e-05	7.19e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1e-05	7.1e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT1—type 2 diabetes mellitus	9.97e-06	7.08e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT1—type 2 diabetes mellitus	9.93e-06	7.05e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.81e-06	6.96e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	9.8e-06	6.96e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—SRC—type 2 diabetes mellitus	9.74e-06	6.91e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—INS—type 2 diabetes mellitus	9.7e-06	6.89e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL2—type 2 diabetes mellitus	9.55e-06	6.78e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF1—type 2 diabetes mellitus	9.39e-06	6.66e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT2—type 2 diabetes mellitus	9.38e-06	6.66e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	9.18e-06	6.52e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SRC—type 2 diabetes mellitus	8.99e-06	6.38e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	8.91e-06	6.33e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	8.87e-06	6.29e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	8.87e-06	6.29e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	8.87e-06	6.29e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	8.87e-06	6.29e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGFR—type 2 diabetes mellitus	8.53e-06	6.06e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOS3—type 2 diabetes mellitus	8.51e-06	6.04e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	8.51e-06	6.04e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	8.5e-06	6.03e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TGFB1—type 2 diabetes mellitus	8.03e-06	5.7e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RELA—type 2 diabetes mellitus	8.01e-06	5.69e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	7.9e-06	5.61e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGFR—type 2 diabetes mellitus	7.88e-06	5.59e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—type 2 diabetes mellitus	7.54e-06	5.35e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	7.38e-06	5.24e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	7.23e-06	5.13e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	7.23e-06	5.13e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CASP3—type 2 diabetes mellitus	7.22e-06	5.13e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	7.09e-06	5.03e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	7.04e-06	5e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	7.04e-06	5e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	7.04e-06	5e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	7e-06	4.97e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.95e-06	4.94e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	6.87e-06	4.88e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.83e-06	4.85e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	6.8e-06	4.82e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.75e-06	4.79e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—type 2 diabetes mellitus	6.56e-06	4.66e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	6.32e-06	4.48e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	6.32e-06	4.48e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	6.32e-06	4.48e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SRC—type 2 diabetes mellitus	6.29e-06	4.47e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	6.2e-06	4.4e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	6.15e-06	4.36e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.13e-06	4.35e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—type 2 diabetes mellitus	6.05e-06	4.3e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT1—type 2 diabetes mellitus	6.05e-06	4.29e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	6.01e-06	4.27e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	5.78e-06	4.1e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	5.71e-06	4.06e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	5.71e-06	4.06e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.63e-06	3.99e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT1—type 2 diabetes mellitus	5.59e-06	3.96e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.52e-06	3.92e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	5.48e-06	3.89e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	5.48e-06	3.89e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.72e-06	3.35e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	4.72e-06	3.35e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	4.7e-06	3.34e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	4.64e-06	3.29e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	4.5e-06	3.2e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	4.38e-06	3.11e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	4.3e-06	3.05e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—type 2 diabetes mellitus	4.24e-06	3.01e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	4.21e-06	2.99e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	4.19e-06	2.98e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	4.08e-06	2.9e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	4.03e-06	2.86e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.91e-06	2.78e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	3.87e-06	2.75e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	3.8e-06	2.7e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	3.68e-06	2.61e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	3.62e-06	2.57e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	3.6e-06	2.56e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	3.56e-06	2.53e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	3.14e-06	2.23e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	3.08e-06	2.18e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	2.82e-06	2e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	2.7e-06	1.92e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	2.7e-06	1.92e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	2.47e-06	1.75e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.24e-06	8.81e-06	CbGpPWpGaD
